A prospective study of high-frequency auditory function in patients receiving oral neomycin.
Orally administered, neomycin is reported to cause ototoxicity rarely. Most reports on hearing loss due to oral neomycin have been case studies. One prospective study of a pediatric sample demonstrated a significant loss of hearing in the frequency range of 2 to 8 kHz in 9 of 17 children. To our knowledge there are no published prospective studies on this type with adult samples and therefore little is known of the true incidence or nature of ototoxicity from oral neomycin. This prospective study presents the results of long-term use of oral neomycin in 30 adult subjects. Hearing sensitivity was serially monitored in the frequency range 250-20,000 Hz. Two of the 30 subjects subsequently revealed ototoxicity. Thus the results of this investigation suggest that clinical use of oral neomycin implies relatively little risk of ototoxicity.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001168:Arthritis / Q000188:drug therapy; D016918:Arthritis, Reactive / Q000188:drug therapy; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D001301:Audiometry, Pure-Tone; D001309:Auditory Threshold / Q000187:drug effects; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D034381:Hearing Loss / Q000139:chemically induced*; D006316:Hearing Loss, High-Frequency / Q000139:chemically induced*; D006801:Humans; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D009355:Neomycin / Q000009:adverse effects* / Q000627:therapeutic use; D011446:Prospective Studies; D011565:Psoriasis / Q000188:drug therapy; D011897:Random Allocation; D013167:Spondylitis, Ankylosing / Q000188:drug therapy
D009355:Neomycin